For research use only. Not for therapeutic Use.
Forodesine hydrochloride (Cat No.:I002969) is a potent and selective inhibitor of purine nucleoside phosphorylase (PNP). It exerts its pharmacological activity by blocking the conversion of inosine and deoxyinosine to hypoxanthine and deoxyguanosine, respectively, leading to intracellular accumulation of these nucleosides. This disruption of purine metabolism results in T-cell-specific immunosuppression and apoptosis, making Forodesine hydrochloride a potential therapeutic agent for T-cell malignancies and autoimmune disorders. In clinical trials, Forodesine hydrochloride has demonstrated efficacy in treating cutaneous T-cell lymphoma and T-cell prolymphocytic leukemia. It is typically administered orally or intravenously and has shown manageable adverse effects, including hematological toxicities.
| Catalog Number | I002969 |
| CAS Number | 284490-13-7 |
| Molecular Formula | C11H15ClN4O4 |
| Purity | ≥95% |
| Target | PNP(Purine nucleoside phosphorylase) |
| Solubility | H2O: ≥ 74.1 mg/mL |
| Storage | 3 years -20C powder |
| Related CAS | 209799-67-7(free base) |
| IUPAC Name | 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one;hydrochloride |
| InChI | InChI=1S/C11H14N4O4.ClH/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19;/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19);1H/t5-,7+,9-,10+;/m1./s1 |
| InChIKey | WEIAMZKHBCLFOG-QPAIBFMUSA-N |
| SMILES | C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O.Cl |
| Reference | 1: Lewis DJ, Duvic M. Forodesine in the treatment of cutaneous T-cell lymphoma. </br> </br> </br> 5: Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi F. Forodesine: review of </br> |
